Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
Portfolio Pulse from Vandana Singh
Artiva Biotherapeutics (NASDAQ:ARTV) recently priced its IPO at $12.00 per share, raising approximately $167 million. The company focuses on developing cell therapies for autoimmune diseases and cancers, with its lead program, AlloNK, currently in clinical trials. Needham and Wedbush have initiated coverage with bullish ratings and price targets of $23 and $18, respectively. Initial clinical results for AlloNK in lupus are expected in the first half of 2025.
August 13, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Artiva Biotherapeutics raised $167 million in its IPO and received bullish coverage from Needham and Wedbush. The company's lead program, AlloNK, is in clinical trials for autoimmune diseases, with initial results expected in 2025.
The IPO raised significant capital, and the bullish ratings from Needham and Wedbush, along with promising clinical trials, are likely to positively impact ARTV's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100